DISTREPTAZA and pelvic pain

Comparison the impact of DISTREPTAZA and a placebo on pelvic pain after laparoscopic surgery in cases of endometriosis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20091012002576N51

Enrollment

Registered

2025-01-24

Start date

2024-09-22

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis and pelvic pain. Endometriosis of pelvic peritoneum

Interventions

Intervention 1: Intervention group: Following laparoscopy for endometriosis, participants are prescribed suppository rectal distreptaza 2g for 9 days,(3 days,TDS, 3days BD,3 days daily) , then pelvic

Eligibility

Sex/Gender

Female

Age

18 Years to 42 Years

Inclusion criteria

Inclusion criteria: Approved endometriosis by pathology Pelvic pain

Exclusion criteria

Exclusion criteria: Hypersensitivity to distreptaza BMI>30 Diabetes melitus Hydrosalpinx

Design outcomes

Primary

Measure	Time frame
Pelvic pain. Timepoint: Two weeks after intervention. Method of measurement: By questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Davari Tanha

Tehran University of Medical Sciences

Fatedavtanha@gmail.com+98 21 8880 0115

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026